## Beta-Blocker Selectivity Classification **Key Point:** Beta-blockers are classified by their receptor selectivity. Selectivity for β1-receptors (cardiac) over β2-receptors (bronchial/vascular smooth muscle) is clinically important to minimize bronchospasm risk. ### Selective β1-Blockers (Cardioselective) These agents preferentially block β1-adrenergic receptors at therapeutic doses, preserving β2-mediated bronchodilation: | Agent | Selectivity | Clinical Advantage | |-------|-------------|-------------------| | Metoprolol | β1-selective | Safer in asthma/COPD at low doses | | Atenolol | β1-selective | Longer half-life, once-daily dosing | | Bisoprolol | β1-selective | Highest cardioselectivity ratio | | Carvedilol | **Non-selective** | Blocks β1, β2, AND α1-receptors | ### Carvedilol: The Exception Carvedilol is a **non-selective beta-blocker with additional α1-blocking activity**. It blocks: - β1-adrenergic receptors (cardiac) - β2-adrenergic receptors (bronchial/vascular) - α1-adrenergic receptors (vasodilation) **Clinical Pearl:** Carvedilol's α1-blocking property causes vasodilation and is beneficial in heart failure (reduces afterload), but it loses the cardioselective advantage and carries higher bronchospasm risk in obstructive airway disease. **High-Yield:** In NEET PG exams, carvedilol is frequently tested as the "odd one out" among β1-selective agents because of its combined α1-blocking property and non-selective β-blockade. ### Why Selectivity Matters At therapeutic doses, β1-selective agents spare β2-receptors on bronchial smooth muscle, reducing the risk of bronchospasm in asthmatic patients. Carvedilol, being non-selective, blocks β2-receptors and increases this risk significantly.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.